国投证券股份有限公司 关于深圳市倍轻松科技股份有限公司 使用闲置募集资金与自有资金购买理财产品的核查意见 国投证券股份有限公司（以下简称"国投证券"、"保荐机构"）作为深圳 市倍轻松科技股份有限公司（以下简称"倍轻松"、"公司"）首次公开发行股 票并在科创板上市持续督导阶段的保荐机构，根据《证券发行上市保荐业务管理 办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证 券交易所科创板股票上市规则》等有关规定，对倍轻松使用闲置募集资金与自有 资金购买理财产品事项进行了审慎核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可〔2021〕1965 号文核准，并经上海证券 交易所同意，公司由主承销商国投证券股份有限公司采用询价方式，向社会公众 公开发行股份人民币普通股(A 股)股票 15,410,000 股，发行价为每股人民币 27.40 元，共计募集资金 422,234,000.00 元，坐扣不含税承销和保荐费用 31,556,380.00 元后的募集资金为 390,677,620.00 元， ...

上海君澜律师事务所 关于 深圳市倍轻松科技股份有限公司 2022 年限制性股票激励计划作废限制性股票 之 法律意见书 二〇二五年四月 上海君澜律师事务所 法律意见书 上海君澜律师事务所 关于深圳市倍轻松科技股份有限公司 2022 年限制性股票激励计划作废限制性股票之 法律意见书 致：深圳市倍轻松科技股份有限公司 上海君澜律师事务所（以下简称"本所"）接受深圳市倍轻松科技股份有 限公司（以下简称"公司"或"倍轻松"）的委托，根据《上市公司股权激励 管理办法》（以下简称"《管理办法》"）《上海证券交易所科创板股票上市 规则》（以下简称"《上市规则》"）《科创板上市公司自律监管指南第 4 号—股权激励信息披露》（以下简称"《监管指南》"）及《深圳市倍轻松科 技股份有限公司 2022 年限制性股票激励计划》（以下简称"《激励计划》"或 "本次激励计划"）的规定，就倍轻松关于作废本次激励计划已授予但尚未归 属的限制性股票及预留的限制性股票（以下简称"本次作废"）相关事项出具 本法律意见书。 对本法律意见书，本所律师声明如下： （一）本所律师依据《中华人民共和国证券法》《律师事务所从事证券法 律业务管理办法》和《律师事务 ...

北京金诚同达(深圳)律师事务所 关于 深圳市倍轻松科技股份有限公司 2023 年限制性股票激励计划部分 已授予尚未归属的限制性股票作废事项的 法律意见书 北京金诚同达(深圳)律师事务所 关于深圳市倍轻松科技股份有限公司 2023 年限制性股票激励计划部分 已授予尚未归属的限制性股票作废事项的 法律意见书 金深法意字[2025]第[02号 by同天室 | 深圳市福田区鹏程一路广电金融中心 42 层 518000 电话: 0755-2223 5518 传真: 0755-2223 5528 金诚同达律师事务所 法律意见书 金深法意字[2025]第 号 致:深圳市倍轻松科技股份有限公司 北京金诚同达(深圳)律师事务所(以下简称"本所")接受深圳市倍轻松 科技股份有限公司(以下简称"倍轻松"或"公司"）的委托,作为公司实施 2023 年限制性股票激励计划(以下简称"本次激励计划")的特聘专项法律顾 间,根据《中华人民共和国公司法》(以下简称"《公司法》")、《上市公司股 权激励管理办法》(以下简称"《管理办法》")等相关法律、法规、规范性文 件及《深圳市倍轻松科技股份有限公司章程》《深圳市倍轻松科技股份有限公司 202 ...

一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 二、关于募集资金年度存放与使用情况的专项报告…………… 第 3—11 页 三、附件……………………………………………………………第 12—15 页 （一）本所执业证书复印件………………………………………第 12 页 （二）本所营业执照复印件………………………………………第 13 页 （三）本所注册会计师执业证书复印件……………………第 14—15 页 募集资金年度存放与使用情况鉴证报告 天健审〔2025〕3-397 号 目 录 深圳市倍轻松科技股份有限公司全体股东： 我们鉴证了后附的深圳市倍轻松科技股份有限公司（以下简称倍轻松公司） 管理层编制的 2024 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供倍轻松公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为倍轻松公司年度报告的必备文件，随同其他文件一起 报送并对外披露。 二、管理层的责任 倍轻松公司管理层的责任是提供真实、合法、完整的相关资料，按照《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管 ...

| 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 马学军 | 3478.79 | 40.48 | 不变 | | 宁波赫廷投资有限公司 | 634.00 | 7.38 | -10.00 | | 宁波倍松投资有限公司 | 545.55 | 6.35 | 不变 | | 汪荞青 | 481.15 | 5.60 | 不变 | | 宁波日松企业管理合伙企业(有限合伙) | 376.53 | 4.38 | 不变 | | 宝盈核心优势混合A | 83.58 | 0.97 | 新进 | | 宁波倍润投资有限公司 | 68.19 | 0.79 | 不变 | | 深圳市嘉霖信业股权投资管理有限公司-深圳市嘉信元德股 | | | | | 权投资基金合伙企业(有限合伙) | 63.40 | 0.74 | -1.00 | | 李虎 | 56.62 | 0.66 | 新进 | | 永赢科技驱动A | 48.69 | 0.57 | 新进 | | 较上个报告期退出前十大股东有 | | | | | 深圳红钧资本管理有限公司-红钧资本成 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥197,014,270.73, a decrease of 32.83% compared to ¥293,298,831.57 in the same period last year[3]. - The net profit attributable to shareholders was -¥1,832,539.23, representing a decline of 111.74% from ¥15,610,139.93 year-over-year[3]. - The net cash flow from operating activities was -¥61,743,909.04, a significant drop of 249.34% compared to ¥41,344,340.75 in the previous year[3]. - The basic earnings per share were -¥0.02, a decrease of 111.11% from ¥0.18 in the same period last year[3]. - The diluted earnings per share also stood at -¥0.02, reflecting the same decline of 111.11%[4]. - The weighted average return on equity was -0.50%, a decrease of 4.28 percentage points from 3.78% in the previous year[4]. - The net profit for Q1 2025 was a loss of ¥1,799,351.33, compared to a profit of ¥15,610,102.87 in Q1 2024[20]. - The company reported total comprehensive income of 2,615,933.08 RMB for the period, a decrease from 7,117,100.71 RMB in the previous period[29]. Assets and Liabilities - Total assets at the end of the reporting period were ¥620,184,156.97, down 23.56% from ¥811,387,085.16 at the end of the previous year[4]. - As of March 31, 2025, the company's total assets amounted to RMB 620,184,156.97, a decrease from RMB 811,387,085.16 as of December 31, 2024, representing a decline of approximately 23.5%[14]. - The company's current assets totaled RMB 472,153,536.87, down from RMB 659,873,627.43, indicating a decrease of about 28.5%[15]. - Total liabilities decreased to ¥247,948,593.04 in Q1 2025 from ¥441,348,946.74 in Q1 2024[17]. - The company's total liabilities decreased to 364,950,797.95 RMB from 464,926,360.60 RMB in the previous period[27]. Cash Flow - The net cash flow from investment activities was 29,391,441.42 RMB, a significant improvement compared to a net outflow of 33,700,550.94 RMB in the previous period[23]. - Total cash inflow from financing activities reached 126,560,000.00 RMB, up from 80,000,000.00 RMB in the prior period[23]. - The company reported a net decrease in cash and cash equivalents of 81,650,291.02 RMB, compared to a smaller decrease of 3,813,744.59 RMB in the previous year[23]. - The net cash flow from operating activities for Q1 2025 was -90,564,306.60 RMB, a significant decline compared to 25,231,971.03 RMB in Q1 2024[32]. - The company reported a total cash outflow from operating activities of 271,977,251.86 RMB in Q1 2025, compared to 297,217,352.04 RMB in Q1 2024, indicating a decrease of about 8.5%[32]. Research and Development - Research and development expenses totaled ¥13,253,647.44, accounting for 6.73% of operating revenue, an increase of 1.62 percentage points from 5.11% in the previous year[4]. - Research and development expenses for Q1 2025 were ¥13,253,647.44, down from ¥14,897,402.33 in Q1 2024[19]. - Research and development expenses for Q1 2025 were 11,657,808.97 RMB, slightly lower than 12,313,360.45 RMB in Q1 2024[28]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,381[9]. - The top shareholder, Ningbo Heting Investment Co., Ltd., holds 6,340,000 shares, representing 7.38% of total shares[12]. - The company reported a total of 1,531,321 shares held in the repurchase account, which are not included in the top 10 shareholders list[10]. - The company has not reported any changes in the top 10 shareholders due to securities lending activities[13].

Financial Performance - The company reported a negative cumulative undistributed profit as of the end of 2024, leading to no profit distribution, cash dividends, or capital reserve transfers for the year[3]. - The company has not achieved profitability since its listing, indicating ongoing financial challenges[3]. - The company's operating revenue for 2024 was approximately ¥1.085 billion, a decrease of 14.88% compared to ¥1.275 billion in 2023[21]. - The net profit attributable to shareholders for 2024 was ¥10.25 million, a significant improvement from a loss of ¥50.87 million in 2023[21]. - The basic earnings per share for 2024 was ¥0.12, compared to a loss of ¥0.60 per share in 2023[22]. - The company's total assets increased by 8.39% to approximately ¥811.39 billion in 2024, up from ¥748.59 billion in 2023[21]. - The company's net assets attributable to shareholders decreased by 8.55% to approximately ¥370.04 million at the end of 2024, down from ¥404.65 million at the end of 2023[21]. - The company achieved revenue of 1,085.12 million yuan and net profit of 10.19 million yuan, marking a turnaround from loss to profit year-on-year[30]. - The company reported a net profit of ¥15.61 million in Q1 2024, with a decline in profits in subsequent quarters[28]. - The company reported a significant increase in other income by 260.13% to ¥30,763,845.11, mainly from government subsidies[144]. Risk Management - The company has detailed various risks and countermeasures in its report, highlighting the importance of risk management in its operations[3]. - The company has faced non-operating fund occupation by controlling shareholders and other related parties[5]. - The company has not reported any violations of decision-making procedures regarding external guarantees[5]. - The company is at risk of losing core competitiveness if it fails to keep up with technological advancements in the industry[114]. - The company faces intensified competition in the smart portable massager industry, necessitating continuous innovation and market adaptation[115]. - The gross margin has decreased due to various factors, and there is a risk of further decline if competitive pressures increase[117]. - The company has a high sales expense ratio due to its direct sales model, which may continue to impact overall profitability[118]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance, indicating a standard governance structure[4]. - The governance structure includes various committees to enhance decision-making efficiency[171]. - The company has established a governance structure compliant with relevant laws and regulations, ensuring effective operation of the general meeting, board of directors, and supervisory board[171]. - The company has not reported any significant changes in the independence of its operations or any major competition issues with its controlling shareholders[176]. - There were no changes in the shareholding of directors and senior management during the reporting period[176]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 797.24 million RMB[186]. - The total remuneration for core technical personnel at the end of the reporting period was 165.34 million RMB[186]. - The company held a total of 8 board meetings during the year, with all resolutions passed without any objections[189]. - The audit committee convened 5 meetings during the reporting period to discuss the annual report and internal audit plans[191]. Research and Development - Research and development expenses accounted for 5.38% of operating revenue in 2024, an increase of 0.79 percentage points from 4.59% in 2023[23]. - Total R&D investment amounted to ¥58,345,886.58, a slight decrease of 0.27% compared to the previous year, with R&D investment as a percentage of operating income increasing to 5.38% from 4.59%[92]. - The company has 105 R&D personnel, accounting for 11.03% of the total workforce, down from 11.55% in the previous year[95]. - The company applied for 29 invention patents and obtained 24 invention patent authorizations during the reporting period, bringing the total number of various intellectual property rights to 1,919, including 863 authorized patents[89]. - The company has established partnerships with research institutions to accelerate technological innovation and product development, ensuring a competitive edge in the market[83]. - The company’s new product development includes a focus on AI health detection and user interaction improvements[94]. - The company has developed four core systems: Breo Super Bionic, Breo Hyper Motion, Breo TCMDT, and Breo Pro-Health-M, enhancing its technological capabilities in the portable massage device sector[79][80]. Product Development and Innovation - The company launched a laser hair care massage comb registered with the FDA, utilizing low-level laser therapy (LLLT) to stimulate hair follicles and improve scalp vitality, paving the way for entry into the high-end health market in Europe and the US[30]. - A subscription-based sleep improvement plan was introduced, combining hardware data with cloud health models to create a complete service chain from monitoring to intervention[31]. - The product matrix has been optimized, with over ten new massage products launched, including the N6mini neck and shoulder massager, which won the JD 2024 Annual Lightning New Product Project Gold Award[36]. - The company’s innovative technologies include AI-driven personalized massage experiences and IoT connectivity for remote control and customization through mobile apps[66][68]. - The company is focusing on integrating modern technology with traditional Chinese medicine to innovate portable health products, establishing itself as a leader in the smart portable massager industry[48]. - The company has developed a differentiated strategy combining traditional Chinese medicine with modern technology, enhancing its competitive edge in the market[104]. - The company is committed to a dual-driven technology strategy of "Traditional Chinese Medicine × Technology," aiming to redefine health care through intelligent health companions[161]. Market Expansion and Sales Strategy - The company has established a multi-channel sales strategy, leveraging both traditional and emerging e-commerce platforms to drive sales growth[40]. - The company is transitioning its offline stores to a new model that combines technology products with quick-effect massage services, enhancing consumer experience and brand loyalty[39]. - The company has established a diversified business matrix covering "smart hardware + rapid massage services + health AI + pan-health ecosystem" to enhance its strategic positioning[158]. - The company plans to accelerate its global market expansion, focusing on Southeast Asia and the Middle East, with a goal to establish a comprehensive sales network by 2025[166]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a focus on companies in the health tech sector[182]. - The company is enhancing its digital marketing efforts, aiming for a 40% increase in online sales channels[182]. - The company has successfully expanded its market presence, selling its products in regions such as Europe, the United States, Japan, and Southeast Asia, enhancing its global footprint[106]. Customer Engagement and Satisfaction - User data showed a total of 5 million active users, representing a 15% increase compared to the previous quarter[178]. - Customer satisfaction ratings improved to 90%, indicating a strong brand loyalty among users[178]. - The company is enhancing its user service system, focusing on personalized recommendations and improving customer satisfaction feedback mechanisms[169]. Future Outlook - The company provided an optimistic outlook, projecting a revenue growth of 20% for the next fiscal year[178]. - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[182]. - New product launches are expected to contribute an additional $50 million in revenue over the next year[178]. - The company plans to enhance its product line, which currently includes smart portable massagers for various body parts, and plans to introduce more age-friendly products to cater to the growing elderly population[163]. - The company aims to reduce operational costs by 15% through efficiency improvements in the supply chain[178]. - The company is investing in R&D for innovative products, with a budget allocation of $10 million for the upcoming year[181]. Employee Management and Training - The total number of employees in the parent company is 244, while the total number of employees in major subsidiaries is 708, resulting in a combined total of 952 employees[198]. - The company follows a competitive and fair compensation policy, aiming to attract and retain core talent through a comprehensive salary and benefits system[199]. - The training plan for 2024 focuses on enhancing employees' professional skills, management capabilities, and innovative abilities, aligning with the company's strategic goals[200]. - New employee training includes courses on corporate culture, business processes, and practical internships to facilitate smooth onboarding[200].

本人梁文昭，作为深圳市倍轻松科技股份有限公司（以下简称"公司"）的 独立董事，2024 年度，本人严格按照《中华人民共和国公司法》《中华人民共 和国证券法》《上海证券交易所科创板股票上市规则》《上市公司独立董事管理 办法》等法律、法规以及《深圳市倍轻松科技股份有限公司章程》等要求，谨慎、 忠实、勤勉地履职尽责，努力发挥独立董事的作用，审慎认真地行使公司和股东 所赋予的权利，及时关注公司经营情况，积极参加股东大会、董事会及专门委员 会会议，对公司董事会审议的相关重大事项发表公正、客观的独立意见，维护公 司和中小股东的合法权益，为公司的长远发展出谋划策，对董事会的科学决策、 规范运作以及公司发展起到了积极作用。现将本人在 2024 年度履行独立董事职 责的情况报告如下： 深圳市倍轻松科技股份有限公司 深圳市倍轻松科技股份有限公司 2024 年度独立董事述职报告 （独立董事：梁文昭） 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 梁文昭，1970 年 11 月出生，中国国籍，无境外永久居留权，研究生学历。 1993 年至 2002 年，任安达信会计师事务所高级经理。2002 年 11 月至 20 ...

深圳市倍轻松科技股份有限公司 深圳市倍轻松科技股份有限公司 2024 年度独立董事述职报告 （独立董事：陈晓峰） 本人陈晓峰，作为深圳市倍轻松科技股份有限公司（以下简称"公司"）的 独立董事，2024 年度，本人严格按照《中华人民共和国公司法》《中华人民共 和国证券法》《上海证券交易所科创板股票上市规则》《上市公司独立董事管理 办法》等法律、法规以及《深圳市倍轻松科技股份有限公司章程》等要求，谨慎、 忠实、勤勉地履职尽责，努力发挥独立董事的作用，审慎认真地行使公司和股东 所赋予的权利，及时关注公司经营情况，积极参加股东大会、董事会及专门委员 会会议，对公司董事会审议的相关重大事项发表公正、客观的独立意见，维护公 司和中小股东的合法权益，为公司的长远发展出谋划策，对董事会的科学决策、 规范运作以及公司发展起到了积极作用。现将本人在 2024 年度履行独立董事职 责的情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 陈晓峰，1965 年 10 月出生，无境外永久居留权，本科学历。1988 年 7 月至 1994 年 6 月，赣南医学院第一附属医院泌尿外科担任住院医师、主治医师；19 ...

深圳市倍轻松科技股份有限公司 深圳市倍轻松科技股份有限公司 2024 年度独立董事述职报告 （独立董事：李勇） 本人李勇，作为深圳市倍轻松科技股份有限公司（以下简称"公司"）的独 立董事，2024 年度，本人严格按照《中华人民共和国公司法》《中华人民共和 国证券法》《上海证券交易所科创板股票上市规则》《上市公司独立董事管理办 法》等法律、法规以及《深圳市倍轻松科技股份有限公司章程》等要求，谨慎、 忠实、勤勉地履职尽责，努力发挥独立董事的作用，审慎认真地行使公司和股东 所赋予的权利，及时关注公司经营情况，积极参加股东大会、董事会及专门委员 会会议，对公司董事会审议的相关重大事项发表公正、客观的独立意见，维护公 司和中小股东的合法权益，为公司的长远发展出谋划策，对董事会的科学决策、 规范运作以及公司发展起到了积极作用。现将本人在 2024 年度履行独立董事职 责的情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 李勇，1957 年 10 月生，中国国籍，无境外永久居留权，本科学历。1981 年 4 月至 1995 年 11 月，任重庆钢铁集团公司党校讲师、经济师；1995 年 11 ...